FOLR1 and non-small cell lung carcinoma: In conclusion, this study shows high concordance rates of FRα expression between primary tumor and corresponding biopsy and metastatic tissue of both breast cancer and NSCLC patients, underscoring applicability of FRα-targeted agents in these patients.